NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Leiomyosarcoma


Return to Library

Free Leiomyosarcoma Articles


Studies from A. Ayhan and colleagues yield new information about leiomyosarcoma



2009 JUL 13 - (NewsRx.com) -- According to a study from Turkey, "To analyze prognostic factors, the role of lymphadenectomy and postoperative adjuvant treatments in patients with uterine leiomyosarcomas (LMS). Sixty-three patients with uterine LMS are retrospectively analyzed with respect to both DFS and OS."

"Multivariate DFS analysis revealed percentage necrosis to be the unique factor to be significant (median DFS was 3.31 years for < 25% necrosis and 0.78 for > 25% necrosis). Multivariate analysis revealed the mitotic counts to be the unique significant factor affecting the OS (median OS was 7.20 and 1.73 years, respectively, for patients with mitotic counts of 1-5 and > 6; respectively). Median DFS was 2.51 years for patients who had undergone lymphadenectomy and 2.36 years for remaining who did not have a lymphadenectomy procedure (P = 0.4). With respect to OS, median values were 2.44 and 3.16 years, respectively (P = 0.7). Number of the resected lymph nodes was also not significant for both OS and DFS. Mitotic counts and percentage necrosis have significant effects on OS and DFS; respectively," wrote A. Ayhan and colleagues.

The researchers concluded: "Neither the performance nor the extent of lymphadenectomy has an effect on patient survival."

Ayhan and colleagues published the results of their research in Archives of Gynecology and Obstetrics (Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas. Archives of Gynecology and Obstetrics, 2009;280(1):79-85).

For additional information, contact M. Gultekin, Cankiri Devlet Hastanesi, Kadin Hastaliklari & Dogum Bolumu, Cankiri, Turkey.

The publisher of the journal Archives of Gynecology and Obstetrics can be contacted at: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany.

Keywords: Turkey, Gynecology, Leiomyosarcoma, Lymphadenectomy, Lymphatic Metastasis, Necrosis, Surgery, Urology.

This article was prepared by OBGYN & Reproduction Week editors from staff and other reports. Copyright 2009, OBGYN & Reproduction Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login